Women's preferences for prevention of bone loss

Journal of Rheumatology

Volumn 32, Issue 6, 2005, Pages 1086-1092

  Fraenkel, Liana ^a,b   Constantinescu, Florina ^c   Oberto Medina, Mayra ^d   Wittink, Dick R ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

Diphosphonates; Osteoporosis; Patient acceptance of healthcare; Postmenopausal

Indexed keywords

VITAMIN;

ADULT; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; EXERCISE; FEMALE; FRACTURE; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; NORMAL HUMAN; OSTEOLYSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROBABILITY; QUESTIONNAIRE; RISK FACTOR;

ADMINISTRATION, ORAL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SATISFACTION; QUESTIONNAIRES; WOMEN'S HEALTH;

EID: 20444485301     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Scheiber LB, Torregrosa L. Evaluation and treatment of postmenopausal osteoporosis. Semin Arthritis Rheum 1998;27:245-61.
2. Ray NF, Chan JK, Thamer M, Melton L Jr. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35.
3. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103(2A):12S-19S.
4. National Osteoporosis Foundation. Disease Statistics 2002. http://www.nof.org/osteoporosis/diseasefacts.htm
5. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA 2001;285:1415-8.
6. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med 1998;128:253-61.
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
8. Ribeiro V, Blakeley J, Laryea M. Women's knowledge and practices regarding the prevention and treatment of osteoporosis. Health Care Women Int 2000;21:347-53.
9. Seeman E. Selection of individuals for prevention of fractures due to bone fragility. Clin Endocrinol Metab 2000;14:233-49.
10. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med 1994;330:1895-6.
11. Suarez-Almazor ME, Conner-Spady B, Kendall CJ, Russell AS, Skeith K. Lack of congruence in ratings of patients' health status by patients and their physicians. Med Decis Making 2001;21:113-21.
12. Lorig KR, Cox T, Cuevas Y, Kraines RG, Britton MC. Converging and diverging beliefs about arthritis: Caucasian patients, Spanish speaking patients, and physicians. J Rheumatol 1984;11:76-9.
13. Pullar T, Wright V, Feely M. What do patients and rheumatologists regard as an 'acceptable' risk in the treatment of rheumatic disease?. Br J Rheumatol 1990;29:215-8.
14. Alarcon GS, McGwin G, Brooks K, et al. Systemic lupus erythematosus in three ethnic groups. Sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analogue scores. Arthritis Rheum 2002;47:408-13.
15. Singh J, Cuttler L. Mincheol S, Silvers JB, Neuhauser D. Medical decision making and the patient: understanding preference patterns for growth hormone therapy using conjoint analysis. Med Care 1998;36:AS31-45.
16. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000;320:1530-3.
17. Fraenkel L, Bogardus ST, Wittink DR. Understanding patient preferences for the treatment of lupus nephritis using adaptive conjoint analysis. Med Care 2001;39:1203-16.
18. Phillips KA, Maddala T, Johnson FR. Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res 2002;37:1681-705.
19. Green PE, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Marketing 1990;54:3-17.
20. Wittink DR, Bergenstuen T. Forecasting with conjoint analysis. In: Armstrong JS, editor. Principles of forecasting: a handbook for researchers and practitioners. Norwell, MA: Kluwer Academic Publishers; 2001.
21. Wittink DR, Cattin P. Commercial use of conjoint analysis: an update. J Marketing 1998;53:91-6.
22. Vogel VG. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res 2001;7:4413s-8s.
23. Costantino JP. Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settings. Ann NY Acad Sci 2001;949:280-5.
24. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001;93:1449-57.
25. Orme B. Sample size issues for conjoint analysis studies. Sequim. WA: Sawtooth Software; 1998.
26. Orme B. CBC/web analysis module and market simulator. Sequim, WA: Sawtooth Software; 2001.
27. Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002;77:1044-52.
28. Bauer DC, Black D, Ensrud K. et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160:517-25.
29. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998;338:485-92.
30. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med 1998;128:253-61.
31. Janis I, Mann L. Decision making: A psychological analysis of conflict, choice and commitment. New York: The Free Press; 1977.
32. Redelmeier DA, Rozin P, Kahneman D. Understanding patients' decisions. Cognitive and emotional perspectives. JAMA 1993;270:72-6.